Effect of an angiotensin receptor antagonist on cerebral blood flow, cerebral perfusion pressure, and systemic and peripheral haemodynamics in patients with acute stroke
| ISRCTN | ISRCTN41456162 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN41456162 |
| Clinical Trials Information System (CTIS) | 2006-005082-19 |
| Protocol serial number | 1.1 |
| Sponsor | University of Nottingham (UK) |
| Funder | British Heart Foundation (BHF) (UK) (ref: PG/05/137/19999) |
- Submission date
- 07/07/2008
- Registration date
- 29/07/2008
- Last edited
- 04/01/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Division of Stroke Medicine
Clinical Sciences Building
City Hospital
Nottingham
NG5 1PB
United Kingdom
| Phone | +44 (0)115 8231769 |
|---|---|
| abc@123.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single centre, interventional, randomised, double blind placebo controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Effect of an angiotensin receptor antagonist on cerebral blood flow, cerebral perfusion pressure, and systemic and peripheral haemodynamics in patients with acute stroke |
| Study acronym | TAST |
| Study objectives | The hypothesis is that it is possible to lower blood pressure in hypertensive patients with acute stroke using telmisartan (an angiotensin receptor antangonist) without reducing cerebral blood flow. |
| Ethics approval(s) | Ethics approval received from the UK National Research Ethics Service - committee LNR1 on the 11th December 2006 (ref: 06/Q2501/228) |
| Health condition(s) or problem(s) studied | Hypertension in acute stroke |
| Intervention | Telmisartan 80 mg once a day or matched placebo. The patients are in the trial for 90 days, and receive treatment for the whole period. |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Telmisartan |
| Primary outcome measure(s) |
Quantitative cerebral blood flow (xenon computed tomography [CT] figure) before and 1.5 hours after first treatment. |
| Key secondary outcome measure(s) |
1. Middle cerebral artery blood flow velocity (MCABFV) and pulsatility index (transcranial doppler [TCD]) |
| Completion date | 30/11/2009 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 34 |
| Key inclusion criteria | 1. Patients must have suffered ischaemic or haemorrhagic stroke 2. Patients must be 18 years of age or over, either sex 3. Onset date of stroke is less than 5 days 4. Systolic blood pressure (BP) greater than 140 mmHg |
| Key exclusion criteria | 1. Less than 18 years of age 2. Normotension or hypotension (systolic BP less than 140 mmHg) 3. Onset date more than 5 days 4. Coma (Scandinavian Stroke Scale [SSS] less than 4) 5. Patients who are of childbearing potential, pregnant or breastfeeding |
| Date of first enrolment | 01/07/2007 |
| Date of final enrolment | 30/11/2009 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
NG5 1PB
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 05/06/2013 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
04/01/2019: The following changes have been made:
1. Publication reference added.
2. EudraCT number added.
